CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Liothyronine sodium +1 moredrug
Likely dose
Liothyronine sodium 25 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02760056
NCT02760056Phase 1Completed
CompareCT.gov

Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study

Oregon Health and Science University·interventional·Posted May 3, 2016·Updated Nov 19, 2018

In Brief

A Phase 1 clinical trial evaluating Liothyronine sodium and Placebo for Multiple Sclerosis. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a phase 1 study evaluating the safety and maximum tolerated dose of Liothyronine (T3) in subjects with multiple sclerosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 3, 2016
Enrollment StartJun 6, 2016
Primary CompletionJan 10, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.2 years ago

Interventions

Liothyronine sodiumdrug

Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.

Placebodrug

Patient will receive a matching placebo to take twice daily for one week.